Treatment of cytokine storm syndrome with IL‐1 receptor antagonist anakinra in a patient with ARDS caused by COVID‐19 infection: A case report

The biological anakinra appears promising to halt cytokine storm syndrome seen in severe courses of COVID‐19. However, immunosuppression with anakinra may facilitate sepsis, necessitating continuous screening for bacterial superinfections.

Detalles Bibliográficos
Autores principales: Kaps, Leonard, Labenz, Christian, Grimm, Daniel, Schwarting, Andreas, Galle, Peter R., Schreiner, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752410/
https://www.ncbi.nlm.nih.gov/pubmed/33363865
http://dx.doi.org/10.1002/ccr3.3307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752410/
https://www.ncbi.nlm.nih.gov/pubmed/33363865
http://dx.doi.org/10.1002/ccr3.3307

Ejemplares similares